Related Experiment Video
Updated: Jul 19, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
[Glinide(s), sulfonylurea(s)].
Masayuki Arakawa1, Takahisa Hirose
1Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 8, 2006
Summary
Postprandial hyperglycemia, a risk factor for diabetic macroangiopathy, may be improved by glinides. These drugs may decrease atherosclerosis markers, with ongoing studies to confirm cardiovascular benefits.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Diseases
Background:
- Diabetic macroangiopathy is linked to hyperglycemia, particularly postprandial hyperglycemia.
- Glinides selectively improve postprandial hyperglycemia, while sulfonylureas target fasting hyperglycemia.
Purpose of the Study:
- To evaluate the impact of glinides on postprandial hyperglycemia and atherosclerosis.
- To explore the potential of glinides in reducing cardiovascular disease risk.
Main Methods:
- Review of current studies on glinides and their effect on carotid intima-media thickness (IMT).
- Analysis of ongoing large-scale intervention studies with glinides.
Main Results:
- Intervention in postprandial hyperglycemia with glinides has shown a decrease in carotid IMT.
- Limited evidence currently exists on glinides reducing cardiovascular disease risk.
Conclusions:
- Glinides show promise in mitigating atherosclerosis markers associated with postprandial hyperglycemia.
- Further research, including large-scale trials, is needed to determine if glinides reduce atherosclerotic events.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...